Two approaches govern the addition of glucagon to AP, either to allow more aggressive insulin delivery while avoiding hypoglycemia and generally aiming for lower glucoses targets or a more conservative approach which uses glucagon only after suspending insulin for low blood glucose in attempt to prevent pre-emptive hypoglycemia (51). The gene discussed is INS; the disease is Hypoglycemia.